Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.70 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.70 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344058 | 0.85 | BAZ2B (0.72) | BAZ2BBAZ2ACA12CA1CA2 | |
| SCHEMBL23675003 | 0.84 | BAZ2B (0.70) | BAZ2BBAZ2ACA12CA1CA2 | |
| SCHEMBL1660685 | 0.83 | TSHR (0.53) | BAZ2BBAZ2ACA12CA1CA2 | |
| SCHEMBL392754 | 0.83 | BAZ2B (1.00) | BAZ2BBAZ2ACA12CA1CA2 | |
| SCHEMBL26235469 | 0.81 | BRD4 (0.49) | BAZ2BBAZ2ACA12CA1CA2 | |
| SCHEMBL23147153 | 0.81 | BAZ2B (0.67) | BAZ2BBAZ2AMAP2K2MAP2K1TSHR | |
| SCHEMBL17156848 | 0.81 | BAZ2B (0.48) | BAZ2BBAZ2ACA12CA1CA2 | |
| SCHEMBL14528963 | 0.80 | BAZ2B (0.65) | BAZ2BBAZ2ACA12CA1CA2 | |
| SCHEMBL17156670 | 0.80 | CA12 (0.49) | BAZ2BBAZ2ACA12CA1CA2 | |
| SCHEMBL17156651 | 0.80 | BAZ2B (0.47) | BAZ2BBAZ2ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2930170-B1 | PYRIDONE COMPOUND FOR USE IN THE TREATMENT OF DERMATOLOGICAL DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-9643952-B2 | Pyridone compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20160166519-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CT NATIONALE DE RECH SCIENT (FR) | 2016-06-16 | — | — | US | disclosed |
| US-20150315172-A1 | PYRIDONE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2930170-A1 | PYRIDONE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-10-14 | — | — | EP | disclosed |
| EP-2251327-B1 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8431574-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-01-17 | — | — | US | disclosed |
| EP-1682138-B3 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120263679-A1 | Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143579-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7517994-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| EP-1682138-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1682138-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | BAZ2B 2035/4885BAZ2A 2292/4885CA12 4882/4885 |
| US-20090131435-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE | NRAS, BRAF, MAPK9 | BAZ2B 1875/4885BAZ2A 2183/4885CA12 4880/4885 |
| US-20090143389-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | BAZ2B 2367/4885BAZ2A 2755/4885CA12 4872/4885 |
| US-20050250782-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | BAZ2B 2141/4885BAZ2A 2301/4885CA12 4876/4885 |
| US-20160166519-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, RBM22, SF3B1 | BAZ2B 1797/4885BAZ2A 2202/4885CA12 4607/4885 |
| US-20150315172-A1 | PYRIDONE COMPOUND | HRH4, HRH3, HRH1 | BAZ2B 435/4885BAZ2A 395/4885CA12 4832/4885 |
| US-20130018075-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, RAF1 | BAZ2B 1430/4885BAZ2A 1479/4885CA12 4869/4885 |
| US-20090143579-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, MAPK9 | BAZ2B 1980/4885BAZ2A 2084/4885CA12 4879/4885 |
| US-20120263679-A1 | Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, CDK9 | BAZ2B 1521/4885BAZ2A 1748/4885CA12 4858/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | BAZ2B 1945/4885BAZ2A 2062/4885CA12 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.